Innovative Technologies for the Treatment of Pulmonary and Heart Failure

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT05090930

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
National Research Center for Cardiac Surgery, Kazakhstan (from the registry)
Registry
  • NCT NCT05090930
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Kazakhstan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05090930. Non-randomized; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2023-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Innovative Technologies for the Treatment of Pulmonary and Heart Failure
Condition
Cardiogenic Shock
Condition
Ventricular Arrythmia
Condition
Cardiac Arrest With Successful Resuscitation
Condition
Sepsis
Condition
Multiple Organ Failure
Condition
Pulmonary Failure
Condition
Decompensated Heart Failure
Condition
Acute Heart Failure
Intervention (Device)
HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection
Intervention (Device)
CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
Lead sponsor
National Research Center for Cardiac Surgery, Kazakhstan (class: other)
Collaborator
Ministry of Education and Science, Republic of Kazakhstan (class: other government)

Record details

Record id
cardio:ct-nct05090930
Content hash
22e7dffcdb3be5c7827f9129c6c87fc7e554d17efd9b9b65aa58e56c88f6d8e3